DRAFT – not reviewed. Not for publication until checked by a medical expert and approved by the CannaQ owner.
CannaQ

CannaQ › Blog › Chronic pain

DRAFT – not reviewed

Cannabis-based medicines and chronic pain: what the systematic reviews say

Two large reviews of randomised trials, including a Cochrane review updated in January 2026, find small or uncertain benefits alongside more frequent side effects.

Chronic painEvidence type: Systematic reviews and meta-analysesLast checked: Status: draft, awaiting medical expert review

Key points

  • A 2026 Cochrane update (21 trials, 2,187 participants) found no clear evidence that THC-dominant or CBD-dominant medicines increase the number of people with at least 50% relief of neuropathic pain. The certainty of this evidence was very low.[1]
  • For balanced THC/CBD medicines, small effects on some outcomes were found with low-certainty evidence, and the authors judged them not clinically relevant.[1]
  • A 2021 BMJ meta-analysis (32 trials, 5,174 adults) found small to very small improvements in pain, physical functioning and sleep with non-inhaled medical cannabis or cannabinoids, along with several transient side effects.[3]
  • Side effects affecting the nervous system, such as dizziness and drowsiness, were consistently more common than with placebo.[1,3]

Why look at reviews?

Single studies of pain can point in different directions. Systematic reviews collect all eligible randomised trials using a fixed method and rate how certain the combined evidence is (here using the GRADE approach).[1,3] On CannaQ's evidence scale, they sit at the top, but only as strong as the trials they include.

Chronic neuropathic pain: the 2026 Cochrane update

The review notes that its estimated population prevalence ranges from 6% to 10%, and that current medicines help only a minority.[1] The 2026 update replaced the 2018 version of the same review.[1,2] It searched the literature up to 29 January 2025 and included 21 double-blind randomised trials with 2,187 adults, lasting 2 to 26 weeks.[1] The authors judged overall risk of bias to be low in six studies, unclear in ten and high in five.[1]

Type of medicine vs placeboWhat the review concludedCertainty
THC-dominantNo clear evidence for an effect on pain relief of 50% or more, global improvement, withdrawals due to side effects or serious side effects. May increase nervous-system side effects.Very low (benefit outcomes); low (nervous-system side effects)
Balanced THC/CBDNo clear evidence for pain relief of 50% or more. May slightly increase "much improved" ratings, 30% pain relief and withdrawals due to side effects; the authors judged these effects not clinically relevant.Very low to low
CBD-dominantNo clear evidence for an effect on pain relief of 50% or more. Other outcomes could go either way.Very low to low

Source for this table: the abstract of the Cochrane review.[1] The review reported no funding.[1]

Chronic pain more broadly: the 2021 BMJ meta-analysis

This review included 32 randomised trials with 5,174 adults with chronic non-cancer pain (28 trials) or cancer-related pain (4 trials). Cannabis was given orally (30 trials) or applied to the skin (2 trials), with follow-up of 1 to 5.5 months.[3]

The review's own disclosures list relationships of some authors with cannabis companies.[3] Readers can check these in the original publication.

Limits of the evidence

  • Most trials were short, lasting weeks to a few months, so long-term benefits and harms remain unclear.[1,3]
  • The 2018 Cochrane review noted that trials often excluded people with a history of substance use problems or other significant illnesses, which limits how well results apply to everyday patients.[2]
  • The two reviews asked different questions (neuropathic pain only, versus chronic pain in general and non-inhaled products) and should not be read as contradicting each other.
  • The BMJ review's estimates concern non-inhaled (oral or topical) products only.[3]

Ongoing research

On 2026-11-17, a ClinicalTrials.gov search for currently recruiting studies of cannabinoids in neuropathic pain returned three registered trials, including a phase 2 proof-of-concept trial run by the US VA Office of Research and Development and a pilot study of cannabidiol in diabetic peripheral neuropathy.[4,5,6] Registration does not mean results exist yet.

Medical disclaimer. Educational content only, not medical advice. CannaQ is independent: it sells nothing and has no sponsors, affiliate links or industry funding. Do not start, stop or change any treatment on your own; talk to a qualified healthcare professional first. Legal status varies by country. This article summarises published research. It does not recommend any treatment, product or dose, and it is not a substitute for advice from a healthcare professional who knows your situation.

References

All identifiers below were retrieved and checked on 2026-11-17 through PubMed E-utilities, the Europe PMC REST API and the ClinicalTrials.gov API v2.

  1. Ateş G, Welsch P, Klose P, Phillips T, Lambers B, Häuser W, Radbruch L. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2026;1(1):CD012182. PMID: 41548880. DOI: 10.1002/14651858.CD012182.pub3.
  2. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. (Superseded by reference 1.) PMID: 29513392. DOI: 10.1002/14651858.CD012182.pub2.
  3. Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. PMID: 34497047. DOI: 10.1136/bmj.n1034.
  4. ClinicalTrials.gov. Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain. Phase 2; recruiting (checked 2026-11-17). NCT05351801.
  5. ClinicalTrials.gov. Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study. Phase 1/2; recruiting (checked 2026-11-17). NCT07298408.
  6. ClinicalTrials.gov. Brain Mechanisms Supporting Cannabis-induced Pain Relief. Early phase 1; recruiting (checked 2026-11-17). NCT04982965.
Review notes (internal, remove before publication): Figures come from the PubMed abstracts only. Author lists, volumes and pages were checked against PubMed esummary on 2026-11-17. Europe PMC shows reference 2 as updated by reference 1. The table simplifies the 2026 Cochrane conclusions; check the wording against the full summary-of-findings tables. Ongoing-trial counts change daily.

← All articles · How CannaQ grades evidence